薬物排出ステント時代のステント血栓症の発生に黒人の民族性は影響しているのでしょうか
Sara D Collins1, Rebecca Torguson, Michael A Gaglia
1Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC 20010, USA.
Circulation
|September 1, 2010
まとめ
黒人人種は,薬物排出ステントの植え付け後にステント血栓症を独立して予測します. この発見は,社会経済的な地位と併発性疾患を考慮した後でも持続し,根本的なメカニズムに関するさらなる研究を正当化しています.
科学分野:
- 心臓病学 心臓病学
- 健康の格差について
- 医学研究 医学研究
背景:
- 以前の研究では,黒人人種が,薬剤排出ステント (DES) 植入後のステント血栓症 (ST) の危険因子である可能性があることが示唆されています.
- 社会経済的な地位や併発性疾患が,この関連性を妨害しているかどうかは不明である.
研究 の 目的:
- 黒人人種が,DESインプランテーション後の明確なSTの独立した予測因子であるかどうかを調査する.
- 社会経済的な地位や併発性疾患が人種とSTの関係に影響を与えているかどうかを判断する.
主な方法:
- DESインプラントを受けた1594人の黒人患者と5642人の非黒人の患者を分析した比較研究.
- 併発症および家庭の平均所得に調整された多変量コックス回帰分析を使用した.
- クロピドグレルのコンプライアンスも,潜在的な混乱要因として評価されました.
主要な成果:
- 黒人患者はより若く,高血圧,糖尿病,慢性腎不全,充血性心不全の罹患率が高かった.
- 黒人患者におけるクロピドグレルの準拠度が高いにもかかわらず,多変量分析では,黒人人種が明らかに遅期のSTの有意な予測要因であることを明らかにした.
- 収入の中央値によって示される社会経済的地位は,STと関連していなかった.
結論:
- 黒人人種は,薬剤排出ステント血栓症の独立した予測因子である.
- 黒人患者におけるクロピドグレルの服従性の高さと社会経済的地位との関連性の欠如は,他のメカニズムが関与している可能性があることを示唆しています.
- STにおけるこの人種的格差に寄与する生物学的またはその他の要因を明らかにするために,さらなる研究が必要である.
関連する概念動画
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
